Purdue Leverages Exicure’s SNA™ Technology Platform to Diversify its Portfolio
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 1 (Table of Contents)
Published: 6 Jan-2017
DOI: 10.3833/pdr.v2017.i1.2215 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Purdue Pharma has inked its second-largest deal to date by partnering with biotech start-up Exicure Therapeutics to develop treatments for psoriasis and other indications by exploiting Exicure’s SNA™ (spherical nucleic acid) technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS